Interim data from an open-label, randomized Phase 2 study evaluating FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) was released. The study focused on 42 evaluable patients who had previously progressed after treatment with PD-1-based immune checkpoint inhibitors. The objective response rate (ORR) was 60% across the study, with Arm A at 58% and Arm B at 61%. Median progression-free survival (mPFS) reached 7.2 months, which is more than double the historical benchmark for this patient population. The safety profile was characterized as favorable, consisting mostly of Grade 1-2 treatment-related adverse events, though one Grade 5 event occurred.